

10. Swinbanks D (1994) Deaths bring clinical trials under scrutiny in Japan. *Nature*, **369**, 697.
11. Ozawa N (1996) Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug – proposals for designing non-clinical and clinical studies – is the non-clinical study useful? *The Journal of Toxicological Sciences*, **21**, 323–329.
12. Ministry of Health and Welfare (1997) *Guidelines for package inserts for prescription drugs, notification no. 606 of Pharmaceutical Affairs Bureau*. Tokyo: Ministry of Health and Welfare.
13. Ministry of Health and Welfare (1997) *Guidelines for package inserts for prescription drugs, notification no. 59 of the safety division, Pharmaceutical Affairs Bureau*. Tokyo: Ministry of Health and Welfare.
14. Ministry of Health and Welfare (1997) *Guidelines for precautions for prescription drugs, notification no. 607 of Pharmaceutical Affairs Bureau*. Tokyo: Ministry of Health and Welfare.
15. Williams D, Feely J (2002) Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. *Clinical Pharmacokinetics*, **41**, 343–370.
16. Scripture CD, Pieper JA (2001) Clinical pharmacokinetics of fluvastatin. *Clinical Pharmacokinetics*, **40**, 263–281.
17. Fujino H, Yamada I, Shimada S, Nagao T, Yoneda M (2002) Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans. *Arzneimittel-Forschung*, **52**, 745–753.
18. Kajinami K, Takekoshi N, Saito Y (2003) Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. *Cardiovascular Drug Reviews*, **21**, 199–215.
19. Bjornsson TD, Callaghan JT, Einolf HJ *et al.* (2003) The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. *Drug Metabolism and Disposition: The Biological Fate of Chemicals*, **31**, 815–832.
20. Neuvonen PJ, Kantola T, Kivisto KT (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. *Clinical Pharmacology and Therapeutics*, **63**, 332–341.
21. Kantola T, Kivisto KT, Neuvonen PJ (1998) Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. *Clinical Pharmacology and Therapeutics*, **64**, 177–182.
22. Fichtenbaum CJ, Gerber JG (2002) Interactions between anti-retroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. *Clinical Pharmacokinetics*, **41**, 1195–1211.
23. Fichtenbaum CJ, Gerber JG, Rosenkranz SL *et al.* (2002) Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. *AIDS (London, England)*, **16**, 569–577.
24. Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM (2001) Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. *Antimicrobial Agents and Chemotherapy*, **45**, 3445–3450.
25. Arnadottir M, Eriksson LO, Thysell H, Karkas JD (1993) Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without cyclosporin. *Nephron*, **65**, 410–413.
26. Campana C, Iacona I, Regazzi MB *et al.* (1995) Efficacy and pharmacokinetics of simvastatin in heart transplant recipients. *The Annals of Pharmacotherapy*, **29**, 235–239.
27. Ichimaru N, Takahara S, Kokado Y *et al.* (2001) Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. *Atherosclerosis*, **158**, 417–423.
28. Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ (2000) Plasma concentrations of active simvastatin acid are increased by gemfibrozil. *Clinical Pharmacology and Therapeutics*, **68**, 122–129.
29. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ (2000) Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. *Clinical Pharmacology and Therapeutics*, **68**, 592–597.
30. Kanathur N, Mathai MG, Byrd RP Jr, Fields CL, Roy TM (2001) Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. *Tennessee Medicine: Journal of the Tennessee Medical Association*, **94**, 339–341.
31. Prueksaritanont T, Vega JM, Zhao J *et al.* (2001) Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. *Journal of Clinical Pharmacology*, **41**, 573–581.
32. Marino MR, Vachharajani NN, Hadjilambris OW (2000) Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects. *Journal of Clinical Pharmacology*, **40**, 875–879.
33. Todd PA, Goa KL (1990) Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. *Drugs*, **40**, 583–607.
34. Lilja JJ, Neuvonen M, Neuvonen PJ (2004) Effects of regular consumption of grapefruit juice on the

- pharmacokinetics of simvastatin. *British Journal of Clinical Pharmacology*, 58, 56–60.
35. Lilja JJ, Kivisto KT, Neuvonen PJ (2000) Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. *Clinical Pharmacology and Therapeutics*, 68, 384–390.
  36. Lilja JJ, Kivisto KT, Neuvonen PJ (1998) Grapefruit juice–simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. *Clinical Pharmacology and Therapeutics*, 64, 477–483.
  37. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P (2000) Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. *Clinical Pharmacology and Therapeutics*, 68, 391–400.
  38. Kantola T, Kivisto KT, Neuvonen PJ (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. *Clinical Pharmacology and Therapeutics*, 64, 58–65.
  39. Siedlik PH, Olson SC, Yang BB, Stern RH (1999) Erythromycin coadministration increases plasma atorvastatin concentrations. *Journal of Clinical Pharmacology*, 39, 501–504.
  40. Asberg A, Hartmann A, Fjeldsa E, Bergan S, Holdaas H (2001) Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. *American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons*, 1, 382–386.
  41. Stern RH, Gibson DM, Whitfield LR (1998) Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. *European Journal of Clinical Pharmacology*, 53, 475–478.
  42. Loi CM, Sedman AJ (1999) Response to Lin and Ito. Effect of troglitazone on atorvastatin pharmacokinetics and pharmacodynamics. *Diabetes Care*, 22, 2105–2106.
  43. Boyd RA, Stern RH, Stewart BH *et al.* (2000) Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. *Journal of Clinical Pharmacology*, 40, 91–98.
  44. Fukazawa I, Uchida N, Uchida E, Yasuhara H (2004) Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. *British Journal of Clinical Pharmacology*, 57, 448–455.
  45. Lilja JJ, Kivisto KT, Neuvonen PJ (1999) Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. *Clinical Pharmacology and Therapeutics*, 66, 118–127.
  46. Kivisto KT, Kantola T, Neuvonen PJ (1998) Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. *British Journal of Clinical Pharmacology*, 46, 49–53.
  47. Kantola T, Backman JT, Niemi M, Kivisto KT, Neuvonen PJ (2000) Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. *European Journal of Clinical Pharmacology*, 56, 225–229.
  48. Goldberg R, Roth D (1996) Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. *Transplantation*, 62, 1559–1564.
  49. Park JW, Siekmeier R, Lattke P, Merz M, Mix C, Schuler S, Jaross W (2001) Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. *Journal of Cardiovascular Pharmacology and Therapeutics*, 6, 351–361.
  50. Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE (1995) Pharmacokinetics of the combination of fluvastatin and gemfibrozil. *The American Journal of Cardiology*, 76, 80A–83A.
  51. Jokubaitis LA (1996) Development and pharmacology of fluvastatin. *British Journal of Clinical Practice*, 77A(Suppl.), 11–15.
  52. Andersson TB, Bredberg E, Ericsson H, Sjöberg H (2004) An evaluation of the in vitro metabolism data for predicting the clearance and drug–drug interaction potential of cyp2c9 substrates. *Drug Metabolism and Disposition: the Biological Fate of Chemicals*, 32, 715–721.
  53. Appel S, Rufenacht T, Kalafsky G, Tetzloff W, Kallay Z, Hitzberger G, Kutz K (1995) Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus. *The American Journal of Cardiology*, 76, 29A–32A.
  54. Deslypere JP (1994) Clinical implications of the biopharmaceutical properties of fluvastatin. *The American Journal of Cardiology*, 73, 12D–17D.
  55. Smith HT, Jokubaitis LA, Troendle AJ, Hwang DS, Robinson WT (1993) Pharmacokinetics of fluvastatin and specific drug interactions. *American Journal of Hypertension: Journal of the American Society of Hypertension*, 6, 375S–382S.
  56. Garnett WR, Venitz J, Wilkens RC, Dimenna G (1994) Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin. *The American Journal of Medicine*, 96, 84S–86S.
  57. Olbricht C, Wanner C, Eisenhauer T *et al.* (1997) Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. *Clinical Pharmacology and Therapeutics*, 62, 311–321.
  58. Park JW, Siekmeier R, Merz M *et al.* (2002) Pharmacokinetics of pravastatin in heart-transplant patients

- taking cyclosporin A. *International Journal of Clinical Pharmacology and Therapeutics*, **40**, 439–450.
59. Pan WJ, Gustavson LE, Achari R, Rieser MJ, Ye X, Gutterman C, Wallin BA (2000) Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. *Journal of Clinical Pharmacology*, **40**, 316–323.
  60. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ (2003) Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. *Clinical Pharmacology and Therapeutics*, **73**, 538–544.
  61. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ (2004) Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. *British Journal of Clinical Pharmacology*, **57**, 181–187.
  62. Azie NE, Brater DC, Becker PA, Jones DR, Hall SD (1998) The interaction of diltiazem with lovastatin and pravastatin. *Clinical Pharmacology and Therapeutics*, **64**, 369–377.
  63. Becquemont L, Funck-Brentano C, Jaillon P (1999) Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. *Fundamental & Clinical Pharmacology*, **13**, 232–236.
  64. Pan HY, Triscari J, DeVault AR, Smith SA, Wang-Iverson D, Swanson BN, Willard DA (1991) Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. *British Journal of Clinical Pharmacology*, **31**, 665–670.
  65. Garnett WR (1995) Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. *American Journal of Health-system Pharmacy*, **52**, 1639–1645.
  66. Hasunuma T, Nakamura M, Yachi T, Arisawa N, Fukushima K, Iijima H, Saito Y (2003) The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporin [Article in Japanese]. *Rinsho Iyaku. Journal of Clinical Therapeutics & Medicine*, **19**, 381–389.
  67. Yamazaki H, Fujino H, Kanazawa M, Tamaki T, Sato F, Suzuki M, Kitahara M (2004) Pharmacological and pharmacokinetic features and clinical effects of pitavastatin (Livalo Tablet(R)) [Article in Japanese]. *Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology*, **123**, 349–362.
  68. Stern JM, Simes RJ (1997) Publication bias: evidence of delayed publication in a cohort study of clinical research projects. *BMJ (Clinical research ed.)*, **315**, 640–645.
  69. Lin JH, Lu AY (1998) Inhibition and induction of cytochrome P450 and the clinical implications. *Clinical Pharmacokinetics*, **35**, 361–390.
  70. Wilkinson GR (2001) Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbird LE, Gilman AG, eds. *Goodman and Gilman's the pharmacological basis of therapeutics*, 10th ed. New York: McGraw-Hill, 3–29.
  71. Alfaro CL (2001) Emerging role of drug interaction studies in drug development: the good, the bad, and the unknown. *Psychopharmacology Bulletin*, **35**, 80–93.
  72. Lee AJ, Maddix DS (2001) Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. *The Annals of Pharmacotherapy*, **35**, 26–31.
  73. Terrovitou CT, Milionis HJ, Elisaf MS (1998) Acute rhabdomyolysis after bezafibrate re-exposure. *Nephron*, **78**, 336–337.
  74. Duell PB, Connor WE, Illingworth DR (1998) Rhabdomyolysis after taking atorvastatin with gemfibrozil. *The American Journal of Cardiology*, **81**, 368–369.
  75. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. *Clinical Pharmacology and Therapeutics*, **72**, 685–691.
  76. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ (2001) Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. *Clinical Pharmacology and Therapeutics*, **69**, 340–345.
  77. Niemi M, Neuvonen PJ, Kivisto KT (2001) Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. *Clinical Pharmacology and Therapeutics*, **70**, 439–445.
  78. Becquemont L (2003) Drug interactions with lipid lowering drugs [article in French]. *Therapie*, **58**, 85–90.
  79. Wen X, Wang JS, Backman JT, Kivisto KT, Neuvonen PJ (2001) Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. *Drug Metabolism and Disposition: the Biological Fate of Chemicals*, **29**, 1359–1361.
  80. Prueksaritanont T, Zhao JJ, Ma B et al. (2002) Mechanistic studies on metabolic interactions between gemfibrozil and statins. *The Journal of Pharmacology and Experimental Therapeutics*, **301**, 1042–1051.
  81. Olsson AG, McTaggart F, Raza A (2002) Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. *Cardiovascular Drug Reviews*, **20**, 303–328.
  82. Schneck DW, Birmingham BK, Zalikowski JA et al. (2004) The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. *Clinical Pharmacology and Therapeutics*, **75**, 455–463.
  83. Lin JH, Yamazaki M (2003) Role of P-glycoprotein in pharmacokinetics: clinical implications. *Clinical Pharmacokinetics*, **42**, 59–98.
  84. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T (1993) Human P-glycoprotein transports cyclosporin A and FK506. *The Journal of Biological Chemistry*, **268**, 6077–6080.

85. Wachter VJ, Wu CY, Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. *Molecular Carcinogenesis*, **13**, 129–134.
86. Yamazaki M, Suzuki H, Sugiyama Y (1996) Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. *Pharmaceutical Research*, **13**, 497–513.
87. Dimitroulakos J, Yeager H (1996) HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. *Nature Medicine*, **2**, 326–333.
88. Holmberg M, Sandberg C, Nygren P, Larsson R (1994) Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein. *Anti-cancer Drugs*, **5**, 598–600.
89. Wu X, Whitfield LR, Stewart BH (2000) Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. *Pharmaceutical Research*, **17**, 209–215.
90. Wang E, Casciano CN, Clement RP, Johnson WW (2001) HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. *Pharmaceutical Research*, **18**, 800–806.
91. Li L, Meier PJ, Ballatori N (2000) Oatp2 mediates bi-directional organic solute transport: a role for intracellular glutathione. *Molecular Pharmacology*, **58**, 335–340.
92. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG (1999) A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. *The Journal of Biological Chemistry*, **274**, 37161–37168.
93. Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T, Nishimura K (2001) Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. *The Journal of Pharmacology and Experimental Therapeutics*, **297**, 861–867.
94. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I (2003) Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. *The Journal of Pharmacology and Experimental Therapeutics*, **306**, 703–708.
95. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I (2004) Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. *The Journal of Pharmacology and Experimental Therapeutics*, **308**, 438–445.
96. Ministry of Health, Labor and Welfare (2001) *Methods of drug interaction studies, notification no. 813 of the evaluation and licensing division, Pharmaceutical and Medical Safety Bureau*. Tokyo: Ministry of Health, Labor and Welfare.
97. Center for Drug Evaluation and Research/Center for Biologics Evaluation and Research (1997) *Guidance for industry drug metabolism/drug interaction studies in the drug development process: studies in vitro*, Food and Drug Administration. Rockville, MD: Center for Drug Evaluation and Research/Center for Biologics Evaluation and Research.
98. Center for Drug Evaluation and Research/Center for Biologics Evaluation and Research (1999) *Guidance for industry in vivo drug metabolism/drug interaction studies – study design, data analysis and recommendations for dosing and labeling*, Food and Drug Administration. Rockville, MD: Center for Drug Evaluation and Research/Center for Biologics Evaluation and Research.